It used to be that cost was only one of the many factors that played into the therapeutic decision-making process. That was then, and this is now. Now, for many individuals, cost is the primary factor governing choice of drug treatment. There are many reasons why a patient might fail to achieve optimal seizure control, including such things as drug interactions, treatment-emergent adverse effects, medication nonadherence, and, of course, lack of drug efficacy. Many of these factors we can modify or control. Clinical experience has taught that, for many patients, optimization of treatment requires careful fine-tuning of medication, and that many antiepileptic drugs (AEDs), especially the poorly soluble ones, will display a certain amount of pharmacokinetic variability between patients. The underlying assumption is made, however, that for a given product, pharmacokinetic performance will remain relatively constant between one dose to another. This very fundamental assumption becomes a bit more tenuous, however, when patients frequently switch between different formulations of a given drug. At least, that is the concern. Skeptics will say that this is an unfounded concern and that the guidelines in place by the regulatory bodies should assure us and our patients.
Indeed, one of the most controversial areas in epilepsy therapeutics today is generic substitution. Although generic products do clearly have the potential to offer tremendous cost-savings for patients and third-party payers, this benefit is based on the assumption that a generic product displays essentially the same kinetic and dynamic profile as that of its brand-name counterpart. We ask our patients to trust that the product we are providing is equivalent in every meaningful way as the much more expensive branded product. We further try to assure them that all generic products are created equally, and yes, each prescription refill may look a little different, but it does not matter, as all the tablets are essentially copies of the same thing. It is ironic that clinicians, in an era in which many (if not most) medical organizations as well as schools of pharmacy, medicine, and nursing emphasize evidence-based evaluation of clinical data, are obliged to make these assurances with precious little evidence.
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have concluded that there really does not seem to be any conclusive association between generic substitution and either loss of seizure control or new, treatment-emergent adverse effects (2), although there clearly is a suggestion that when generic substitution occurs, expenditures of resources goes up (3, 4) .
Given this overall lack of evidence that real differences do in fact exist between branded and generic products, how do we reconcile the rather widespread impression among neurologists and many patients to the contrary (5)? It seems that a piece or two of the puzzle is still missing. Fortunately, the recent study by Krauss and colleagues (6) has provided an important and clinically relevant piece of this puzzle.
Using a request under the Freedom of Information Act, the authors obtained pharmacokinetic data submitted to the agency as part of the Abbreviated New Drug Application Process (ANDA) for each of the FDA-approved generic AED formulations. This is noteworthy in that this type of pharmacokinetic data is typically not published in the peer-reviewed literature, nor is it usually available for public inspection.
In this analysis, the authors analyzed the variability of area under plasma concentration time curve (AUC) and maximal peak serum concentration (Cmax) data submitted by generic manufacturers in support of their product. Using this data, Krauss and colleagues were able to model switches between 595 potential pairs of generic-to generic AED formulations.
What they found was interesting. In general, virtually all of the generic AED formulations had systemic exposures (AUCs) that differed by less than 15 percent from their branded, reference counterpart. These investigators also found that peak AED serum concentrations (Cmax) did differ by 15 to 25 percent in almost 11 percent of analyzed studies. Furthermore, generic to reference (brand formulation) ratio for AUC and Cmax differed by 15 to 25 percent in 8.2 percent and 26 percent, respectively when fasting versus fed study conditions were compared. Together, these findings tend to support the FDA position that using current acceptance guidelines (defined as the 90% confidence interval of the log-transformed ratios of AUC and Cmax between brand and generic products falling within 80-125% range), approved A-rated generic products should be expected to provide essentially the same performance as the branded product, at least for most patients. For a small subset of patients, however, variability in kinetic characteristics might be expected to result in significant changes in overall drug exposure. Although this part of the analysis does provide some assurance that in general brand to generic switching is probably acceptable, there is more to the story. An equally important question is whether we can also feel confident when patients are switched between generic products.
Current regulations and testing paradigms are designed to determine whether a given generic formulation is pharmacokinetically equivalent to the brand product. The assumption is made that if generic A is equal to brand and generic B is equal to brand, then it follows that generic A should equal generic B. There is no requirement that individual generic products be directly compared with each other.
In their analysis, Krauss and colleagues also compared estimates of generic with generic switches. They found that although the majority of generic-to-generic pairs had AUC that differed by less than 15 percent 145 did differ by 15 to 25 percent, and 2 percent of generic pairs differed by greater than 25 percent. Even greater variability was seen when looking at peak serum concentrations, where differences in Cmax of 15 to 25 percent were seen in 35 percent of drug pairs. The authors state that based upon these kinetic data, there was a 50 percent probability of seeing 14 or more changes in overall systemic drug exposure (AUC) of greater than 25 percent. The probability of seeing 25 or more changes in Cmax of greater than 25 percent was 56 percent. Not surprisingly, variability seemed greater for the less soluble AEDs such as oxcarbazepine.
This important analysis provides, for the first time, evidence of something that many clinicians have long suspected: it is not necessarily the switch from a branded product to generic that is problematic for some of our patients. Rather, it is the switching between presumably equivalent formulations. Although this clearly was not an efficacy trial, it is not unreasonable to predict that serum drug concentration swings of this magnitude are likely to result in clinical symptoms, particularly in the brittle patient who perhaps is maintained at high serum concentrations in order to achieve seizure control. Interestingly, in a study evaluating healthcare service utilization, Duh and colleagues found that patients having multiple generic switches of topiramate had higher hospitalization rates as compared with brand-only users. Those patients receiving a single version of generic topiramate did not differ from brand-only recipients (7) . Clearly, the analysis by Krauss and colleagues suggest that not all generics are created equal. Although substitution of a single generic product might be expected to result in only modest variability in drug exposure, multiple switches between generic products may be quite another issue.
Although these data are quite compelling, the authors correctly caution against overinterpretation of their results. They were the product of simulations. Some would advocate that current acceptance limits for assigning bioequivalence be narrowed. The question is, narrowed to what? In Denmark, AEDs are designated as narrow therapeutic index drugs, and generic products must meet a more stringent 90 to111 percent acceptance range. Krauss suggests that this standard would have been met for AUC and Cmax by 81 percent and 64 percent of evaluated studies, respectively. Whether this is the best approach will certainly require prospective study.
So, where do we go from here? First, the medical community should push for greater disclosure. Clinicians should not need to resort to the Freedom of Information Act to obtain this crucial information. For physicians and pharmacists to make informed decisions, our professional organizations should insist that manufacturers of narrow therapeutic index generic drugs either publish bioequivalence studies in the literature or at least make them readily accessible. In addition, prospective studies in patients with epilepsy comparing chronic dosing of multiple generic products should be conducted. This type of study would seem necessary to either confirm or refute the observations of Krauss. Until then, it would seem prudent that frequent switching between various generic formulations be discouraged. Pharmacies should be encouraged to try, wherever possible, to purchase generic AEDs from a single manufacturer. This is not a condemnation of generic products. Generic drugs do offer potential savings for patients and payors, and for most of our patients are an acceptable option. Rather, this is an acknowledgment that variability is a fact of biology and will always be a confounding element of pharmacotherapy. The study by Krauss is an important step toward managing the uncertainty and adds another piece of the puzzle.
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